Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Sophie Gasson"'
Autor:
Janet A. Dunn, Sophie Gasson, Sophie Nicholls, Jan Rose, Helen Teresa Edwards, Andrea Marshall, Natalie Hammonds, Beatrix Elsberger, Amit Goyal
Publikováno v:
Breast, Vol 68, Iss , Pp 241-242 (2023)
Externí odkaz:
https://doaj.org/article/6359ef9646734085bde90de382b811b6
Autor:
Helena Earl, Louise Hiller, Anne-Laure Vallier, Shrushma Loi, Karen McAdam, Luke Hughes-Davies, Daniel Rea, Donna Howe, Kerry Raynes, Helen B Higgins, Maggie Wilcox, Chris Plummer, Betania Mahler-Araujo, Elena Provenzano, Anita Chhabra, Sophie Gasson, Claire Balmer, Jean E Abraham, Carlos Caldas, Peter Hall, Bethany Shinkins, Christopher McCabe, Claire Hulme, David Miles, Andrew M Wardley, David A Cameron, Janet A Dunn
Publikováno v:
Health Technology Assessment, Vol 24, Iss 40 (2020)
Background: The addition of adjuvant trastuzumab to chemotherapy has significantly improved outcomes for people with human epidermal growth factor receptor 2 (HER2)-positive, early, potentially curable breast cancer. Twelve months’ trastuzumab, tes
Externí odkaz:
https://doaj.org/article/66820d8dae1b478ea55fa5063313fffe
Publikováno v:
Cureus.
Autor:
Amit Goyal, Sophie Cramp, Andrea Marshall, Duncan Wheatley, Natalie Hammonds, Shama Puri, Tara Homer, Luke Vale, Roeum Butt, Romaana Mir, Janice Rose, Helen Teresa Edwards, Samreen Ahmed, Abeer Shaaban, Beatrix Elsberger, Julie Bruce, Sophie Gasson, Valerie Speirs, Jacqui Shaw, Helen Higgins, Janet Dunn
Publikováno v:
Cancer Research. 82:OT1-04
Background: For patients who are node positive to start at presentation and are found to have a complete nodal tumour response (ypN0) post neoadjuvant chemotherapy (NACT), we do not yet know whether local axillary therapy can be modified based on the
Autor:
Karen Milton, Karen Poole, Ainslea Cross, Sophie Gasson, Kajal Gokal, Karen Lyons, Richard Pulsford, Andy Jones
Objective: This research took a co-design approach to develop a social intervention to support people affected by a cancer diagnosis to be physically active. Methods: We conducted semi-structured interviews with five key stakeholder groups: (1) adult
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75513acf775d16658fcd7223c715e1e9
https://ueaeprints.uea.ac.uk/id/eprint/84044/
https://ueaeprints.uea.ac.uk/id/eprint/84044/
Publikováno v:
European Journal of Surgical Oncology. 48:e197-e198
Autor:
Agnieszka Lemanska, Bruce A. Griffin, Sophie Gasson, Fiona Archer, Karen Poole, Karen S. Lyons, Sara Faithfull, John M. Saxton, Jane Ogden
Publikováno v:
Psycho-Oncology. 28:593-599
Objective It is well established that exercise and lifestyle behaviours improve men's health outcomes from prostate cancer. With 3.8 million men living with the disease worldwide, the challenge is creating accessible intervention approaches that lead
Autor:
Amit Goyal, Sophie Cramp, Andrea Marshall, Natalie Hammonds, Duncan Wheatley, Beatrix Elsberger, Shama Puri, Tara Homer, Luke Vale, Roeum Butt, Zohal Nabi, Janice Rose, Helen Teresa Edwards, Samreen Ahmed, Abeer Shaaban, Julie Bruce, Sophie Gasson, Helen Higgins, Janet Dunn
Publikováno v:
Journal of Clinical Oncology. 40:TPS615-TPS615
TPS615 Background: Neoadjuvant chemotherapy (NACT) results in eradication of cancer in the axillary nodes in 40-70% of patients. This raises questions about the benefit of further axillary treatment in patients with no evidence of residual nodal dise
Autor:
Maggie Wilcox, Luke Hughes-Davies, Peter Hall, David Cameron, Jean Abraham, Daniel Rea, Iain R. Macpherson, E. O'Riordan, Helena M. Earl, Carlos Caldas, Sophie Gasson, Andrew M Wardley, Duncan Wheatley, David Miles, Janine Mansi, Louise Hiller, Janet A. Dunn, Karen McAdam
Publikováno v:
M Earl, H, Hiller, L, Dunn, J, Macpherson, I, Rea, D, Hughes-Davies, L, McAdam, K, Hall, P S, Mansi, J, Wheatley, D, Abraham, J, Caldas, C, Gasson, S, O'Riordan, L, Wilcox, M, Miles, D, Cameron, D A & Wardley, A 2020, ' Optimising the duration of adjuvant trastuzumab in early breast cancer in the UK ', Clinical Oncology . https://doi.org/10.1016/j.clon.2020.07.006
Clinical Oncology (Royal College of Radiologists (Great Britain)
Clinical Oncology (Royal College of Radiologists (Great Britain)
Adjuvant trastuzumab for patients with HER2-positive early breast cancer showed significant improvements in both disease-free and overall survival with 12 months of treatment [1,2], which was approved by the National Institute for Health and Care Exc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e3af2ebe574e814431b74d21efce87c
http://wrap.warwick.ac.uk/138965/2/WRAP-optimising-duration-adjuvant-trastuzumab-early-breast-cancer-UK-Hiller-2020.pdf
http://wrap.warwick.ac.uk/138965/2/WRAP-optimising-duration-adjuvant-trastuzumab-early-breast-cancer-UK-Hiller-2020.pdf
Autor:
Claire Hulme, Sophie Gasson, Andrew M Wardley, David Miles, Chris Plummer, Luke Hughes-Davies, Betania Mahler-Araujo, Christopher McCabe, Daniel Rea, Maggie Wilcox, Donna L. Howe, Elena Provenzano, Karen McAdam, David Cameron, Louise Hiller, Kerry Raynes, A. Chhabra, Jean Abraham, Carlos Caldas, Peter Hall, Bethany Shinkins, Shrushma Loi, Claire E. Balmer, Anne-Laure Vallier, Helena M. Earl, Helen B Higgins, Janet A. Dunn
Publikováno v:
2020, ' Six versus 12 months’ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT ', Health Technology Assessment . https://doi.org/10.3310/hta24400
Health Technology Assessment, Vol 24, Iss 40 (2020)
Health Technol Assess
Health Technology Assessment, Vol 24, Iss 40 (2020)
Health Technol Assess
Background The addition of adjuvant trastuzumab to chemotherapy has significantly improved outcomes in human epidermal growth factor receptor 2 (HER2) positive early, potentially curable breast cancer. Twelve months��� trastuzumab tested in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55c0fc0c5df4f69d837b0b2c879bcd22
https://www.repository.cam.ac.uk/handle/1810/300957
https://www.repository.cam.ac.uk/handle/1810/300957